Search research articles
Contact Us
Filters
Showing results (161-170 of 199) with videos related to
Page
of 20
Sort By:
Blood
|
February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor
Warren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Frontiers in Immunology
|
June 26, 2026
Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease model
Abel Trujillo-Ocampo, Pamella Borges, Maison Grefe, et al.
Blood Advances
|
August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase
Warren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood
|
April 10, 2015
PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia
Jinjun Dang, Lei Wei, Jeroen de Ridder, et al.
Cell Reports. Medicine
|
November 15, 2023
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas
Xiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, et al.
Gastroenterology
|
September 19, 2017
Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway
Jian Chen, Sobia Zaidi, Shuyun Rao, et al.
Blood Neoplasia
|
September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Scientific Reports
|
January 22, 2020
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers
Gabriel G Malouf, Ronan Flippot, Yiyu Dong, et al.
Blood
|
November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML
Warren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Oncotarget
|
November 3, 2016
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Polina Matre, Juliana Velez, Rodrigo Jacamo, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 199) with videos related to
Sort By:
Page
of 20
Blood
|
February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor
Warren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Frontiers in Immunology
|
June 26, 2026
Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease model
Abel Trujillo-Ocampo, Pamella Borges, Maison Grefe, et al.
Blood Advances
|
August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase
Warren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood
|
April 10, 2015
PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia
Jinjun Dang, Lei Wei, Jeroen de Ridder, et al.
Cell Reports. Medicine
|
November 15, 2023
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas
Xiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, et al.
Gastroenterology
|
September 19, 2017
Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway
Jian Chen, Sobia Zaidi, Shuyun Rao, et al.
Blood Neoplasia
|
September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Scientific Reports
|
January 22, 2020
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers
Gabriel G Malouf, Ronan Flippot, Yiyu Dong, et al.
Blood
|
November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML
Warren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Oncotarget
|
November 3, 2016
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Polina Matre, Juliana Velez, Rodrigo Jacamo, et al.
Page
of 20